Medline stock price target reaffirmed at $55 by BTIG

Medline reported Q4 sales of ~$7.89B vs $7.52B consensus (≈+4%) and LTM revenue of $28.4B (+11.5%), with a P/E of ~30. BTIG reaffirmed a Buy and $55 price target (~25% upside from $43.83), while Wolfe Research and Stifel raised targets to $55 after stronger EBITDA and the revenue beat. Major stockholders announced a secondary offering of 75.0M Class A shares at $41.00 with a 11.25M overallotment option (expected close March 10, 2026); Medline will not receive proceeds. BTIG highlighted tariff-related pricing benefits expected in 2026 and a large IDN client consolidation win, supporting operational strength.

Analysis

The large, sponsor-led secondary creates an immediate supply shock that the market is under-pricing: 75m shares (plus a 30-day greenshoe) is likely to represent mid-single-digit percentary dilution relative to outstanding float, which is sufficient to depress near-term price discovery by 10–20% if executed into weak demand. Underwriters’ short-window option amplifies front-loading risk — selling pressure will concentrate around the close date and shortly after lock-up expiration windows for other holders, compressing liquidity and exaggerating volatility in the days-to-weeks horizon.

Medline’s operational footprint (true multi-site distribution and logistics) gives it durable pricing power inside IDNs, so any pullback caused by the secondary is a tactical opportunity only if market participants treat the sale as signaling peak structural growth. The tariff pass-through slated for 2026 is a binary-to-gradual margin event: if realized cleanly it likely adds high-margin dollars, but its translation into EBITDA depends on hospital procurement cycles and one-off contract timing, so expect phased margin recognition across 2–4 quarters rather than an immediate re-rate.

Competitively, the second-order winners are vendors who cannot support full IDN coverage (they lose share) and private-label manufacturers able to scale near-shore capacity — the consolidation trend raises switching-cost barriers that favor Medline over smaller regional distributors. Tail risks: a poorly absorbed secondary, reversal of tariff policy, or a material contract loss at a large IDN could each trigger >30% downside; conversely, clean absorption plus early tariff-driven margin prints could re-rate multiples back toward street targets within 6–12 months.

Key Decisions for Investors

• Short MDLN (stock) into the offering: initiate a 1–2% notional short around current levels (~$44). Target $36 (≈18% downside) with a stop at $50 (≈14% risk). Time horizon: close position within 2–3 weeks after the offering closes (around March 10, 2026) unless material fundamental upside appears.
• Buy a protective put spread on MDLN to monetize near-term downside with capped cost: buy May-2026 $35 puts and sell May-2026 $30 puts (size to limit max premium to <1% portfolio). Rationale: protects through post-offering absorption and Q1 prints; limited downside cost if trade fails, payoff if shares breach low-30s in 2–3 months.
• Event-driven long re-entry plan: plan to accumulate MDLN only on a >25% drawdown from current levels or 90 days after the offering closes, targeting $55 over 12–24 months. Use a 12% hard stop and tranche purchases (50% on first signal, 50% on confirmation) to capture tariff-led EBITDA realization and IDN consolidation upside while managing post-secondary volatility.